Influence of Gut Microbiota and its Metabolites on Progression of Metabolic Associated Fatty Liver Disease.

Author: Yuan-Yuan WANG ¹ ; Hai-Lian LIN ¹ ; Ke-Lang WANG ¹ ; Gen-Xiang QUE ¹ ; Ting CAO ¹ ; La-Mei ZHU ² ; Xia YANG ¹ ; Xue-Feng YANG ¹
Author Information

1. Hunan Provincial Clinical Research Center for Metabolic Associated Fatty Liver Disease, Affiliated Nanhua Hospital, Hengyang Medical School & University of South China, Hengyang, Hunan 421002, China.
2. Department of Hepatobiliary Surgery, Affiliated Nanhua Hospital, Hengyang Medical School & University of South China, Hengyang, Hunan 421002, China.
Publication Type:Journal Article
Keywords: hepatocellular carcinoma; intestinal microorganisms; liver fibrosis; metabolic associated fatty liver disease; non-alcoholic fatty liver disease
MeSH: Gastrointestinal Microbiome; Fatty Liver/microbiology*; Humans
From: Chinese Medical Sciences Journal 2023;38(4):286-296
CountryChina
Language:English
Abstract: Metabolic associated fatty liver disease (MAFLD) has become a prevalent chronic liver disease worldwide because of lifestyle and dietary changes. Gut microbiota and its metabolites have been shown to play a critical role in the pathogenesis of MAFLD. Understanding of the function of gut microbiota and its metabolites in MAFLD may help to elucidate pathological mechanisms, identify diagnostic markers, and develop drugs or probiotics for the treatment of MAFLD. Here we review the pathogenesis of MAFLD by gut microbiota and its metabolites and discuss the feasibility of treating MAFLD from the perspective of gut microbes.